A Randomized, Triple-arm, Controlled, Open-label, Multicenter Phase II Study Assessing Two Different Doses of Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2016
At a glance
- Drugs Panobinostat (Primary) ; Carfilzomib; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PANORAMA-5
- Sponsors Novartis Pharmaceuticals
- 03 Oct 2016 Planned End Date changed from 1 Nov 2020 to 1 Feb 2021.
- 03 Oct 2016 Planned primary completion date changed from 1 Nov 2020 to 1 Feb 2021.
- 03 Oct 2016 Planned initiation date changed from 1 Jun 2016 to 1 Dec 2016.